Liver Disease Treatment Market, By Type (Toxic Injury, Infectious Agents & Parasite, Immune Disorders, Tumors, and Inherited Liver Diseases), By Application (Hospitals & Specialty, and Clinics), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Liver Disease Treatment Market was valued at US$ 19.1 Billion in 2024 and is projected to grow at a CAGR of 6.10% to reach US$ 32.7 Billion by 2034.

Any of various illnesses that can harm liver are referred to as "liver diseases." Cirrhosis can develop over the course of liver illness. The liver can no longer function normally when more scar tissue takes the place of good liver tissue. Liver failure and liver cancer can result from untreated liver illness and viral infections, such as hepatitis A, B, and C, can cause liver damage. Overeating fat causes non-alcohol-related fatty liver disease (NAFLD). As the prevalence of obesity and diabetes rises, NAFLD is becoming more widespread.

The market for liver disease treatment market is anticipated to develop in the future due to the rising prevalence of disorders associated with the liver. Due to factors like widespread heavy alcohol use among most age groups, rising obesity rates brought on by poor daily habits, and irregular eating patterns, there is an increase in cases of liver failure worldwide, which may increase the demand for effective treatments and spur the growth of the target market during the forecast period. For instance, according to National Institute of Health (NIH), Around 2 million people globally pass away from liver disease each year, with 1 million of those fatalities coming from cirrhosis complications, 1 million from viral hepatitis, and 1 million from hepatocellular carcinoma. Together, liver cancer and cirrhosis account for 3.5% of all fatalities worldwide and are the 11th and 16th most common causes of death worldwide, respectively. With 1.6% and 2.1% of the global burden, cirrhosis is one of the top 20 causes of disability-adjusted life years and years of life lost.

Growing elderly population with life-threatening liver problems caused by failure to maintain homeostasis due to structural change or dysfunction is anticipated to fuel the expansion of the market for treatments for liver disease in the future. For instance, according to National Institute of Health, the elderly participants displayed a higher prevalence of NASH (Non- Alcoholic steatohepatitis) than their younger counterparts (56 vs. 72%, P = 0.02), as well as a higher rate of liver fibrosis, according to a study that compared the elderly group aged over 65 years and the nonelderly group from 18 to 64 years old. NAFLD also showed an increasing tendency as one ages. Additionally, the market for treatments for liver disease is anticipated to develop in the next years due to an increase in the incidence of diabetes in the elderly population brought on by ageing and organ failure. 

Rise in Consumption of Alcohol

Due to an increase in alcoholic beverage use among people in the 18 to 50 age range worldwide, the market for treatments for liver disease is anticipated to expand. Hepatitis and cirrhosis, the most severe types of ARLD, can result from drinking alcohol over an extended period of time. According to the 2021 NSDUH (National Survey of Drug Use and Health), 28.6 million adults aged 18 and older (11.3%) in the United States of America had alcohol use disorder over the course of the time. This figure includes 4.9 million Hispanic or Latino adults aged 18 and older, 270,000 American Indian or Alaska Native adults, 118,000 Native Hawaiian or other Pacific Islander adults, 964,000 Asian adults, and 759,000 adults of two or more races.

Restrains of the Liver Disease Treatment Market:

High Treatment Cost

The high cost of treating chronic liver problems presents an economic burden for both the healthcare system and patients, which is anticipated to slow the growth of the market for treating liver disease in the years to come. According to the Advanced Institute of Liver and Biliary Sciences, depending on the locale of treatment, the cost of a liver transplant might vary from 12 lakhs to 3 cores worldwide. Due to the inability to afford expensive treatment and transplant costs, Liver Disease Treatment Market expansion in low-income areas may be constrained.

Liver Disease Treatment Market is segmented based on Type, Application and Region.

Type Insight

On the basis of Type, Liver Disease Treatment Market is segmented Toxic Injury, Infectious Agents & Parasite, Immune Disorders, Tumors, and Inherited Liver Diseases. Infectious Agent and Parasite type segment is expected to dominate the target market growth due to increasing incidences of hepatitis A, Hepatitis B and Hepatitis C worldwide. According to Centers of Disease Control and Prevention (CDC), 296 million people worldwide are living with hepatitis B. 58 million people worldwide are living with hepatitis C.

Application Insights

On the basis of Application, Liver Disease Treatment Market is segmented into Hospitals & Specialty, and Clinics. Hospitals and Specialty Application segment are expected to dominate the target market growth due to increasing burden of patients with chronic liver disorders worldwide and availability of intensive care facilities such as ICU and HDU. 

Regional Insights:

On the basis of region, the Liver Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as rising incidences of liver disorders, growing medical infrastructure. Asia-Pacific region accounted for largest share of hepatitis infections worldwide due to factors such as dense population low quality hygiene in some of the regions, which are anticipated to increase demand for Liver Disease Treatment in the region.

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Toxic Injury, Infectious Agents & Parasite, Immune Disorders, Tumors, and Inherited Liver Diseases By Application - Hospitals & Specialty, and Clinics
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Liver Disease Treatment Market report based on Type, Application and Region:

Liver Disease Treatment Market, By Type:

• Toxic Injury
• Infectious Agents & Parasite
• Immune Disorders
• Tumors
• Inherited Liver Disease

Liver Disease Treatment Market, By Application:

• Hospitals & Specialty
• Clinics

Liver Disease Treatment Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Liver Disease Treatment Market includes, Abbott Laboratories Ltd., Achillion Pharmaceuticals, Inc., Actavis Pharma Inc., Alkermes Plc., Antipodean Pharmaceuticals, Inc., Bayer Healthcare Pharmaceuticals, Inc., Biotest Pharma GmbH, Bristol-Myers Squibb Company., Conatus Pharmaceuticals, Inc., Eli Lilly & Company Ltd.

• In February 2022, The CDRI's "Picroliv" phytopharmaceutical product has been approved for a phase-III clinical trial to treat fatty liver disease. The Indian Council of Medical Research (ICMR) and the Council for Scientific and Industrial Research-Central Drug Research Institute (CSIR-CDRI) will work together to perform the studies.
• In March 2020, Zydus Cadila's new medicine application for "Saroglitazar" to treat a specific liver illness known as NASH (Non-Alcoholic Steatohepatitis), which is a degenerative disease, has been approved by the medicine Controller General of India (DCGI).

• Abbott Laboratories Ltd *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Achillion Pharmaceuticals, Inc.
• Actavis Pharma Inc.
• Alkermes Plc.
• Antipodean Pharmaceuticals, Inc.
• Bayer Healthcare Pharmaceuticals, Inc.
• Biotest Pharma GmbH
• Bristol-Myers Squibb Company
• Conatus Pharmaceuticals, Inc.
• Eli Lilly & Company Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Liver Disease Treatment Strategies
     • Key Questions this Study will Answer

     • • By Type (Toxic Injury, Infectious Agents & Parasite, Immune Disorders, Tumors, and Inherited Liver Diseases)

       • By Application (Hospitals & Specialty, and Clinics)

       • By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

• North America (U.S., Canada)
• Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
• Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Liver Disease Treatment Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• • Abbott Laboratories Ltd.
  • Achillion Pharmaceuticals, Inc.
  • Actavis Pharma Inc. 
  • Alkermes Plc.
  • Antipodean Pharmaceuticals, Inc.
  • Bayer Healthcare Pharmaceuticals, Inc.
  • Biotest Pharma GmbH
  • Bristol-Myers Squibb Company 
  • Conatus Pharmaceuticals, Inc.
  • Eli Lilly & Company Ltd.

The Last Word

• Future Impact
• Contact
• About Us